E7-targeted T cell treatment for HPV-related cancers
E7 TCR-T cell therapy for HPV-associated cancers
This offers people with advanced HPV-related cancers personalized T cells engineered to attack the HPV E7 protein.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-11125763 on NIH RePORTER |
What this research studies
If I join, doctors will collect my own immune cells and reprogram them in the lab with a T-cell receptor that recognizes the HPV E7 protein, then grow many of those cells and infuse them back into me. The treatment is aimed at cancers caused by HPV, including cancers of the cervix, throat, anus, vulva, vagina, and penis that make the E7 protein. Early testing has shown the approach can be given safely and has produced tumor responses in some patients, and this program seeks to treat more people and improve the process. Joining would involve blood collection (leukapheresis), a hospital visit for the cell infusion, and regular follow-up to check for side effects and response.
Who could benefit from this research
Good fit: Ideal candidates are people with advanced or metastatic HPV-positive cancers that express E7 who have exhausted standard treatments and can undergo leukapheresis and cell infusion.
Not a fit: People whose tumors are not driven by HPV/E7, who are too frail for cell therapy, or who cannot travel to the treatment site are unlikely to benefit.
Why it matters
Potential benefit: If successful, the therapy could shrink or eliminate tumors that make the HPV E7 protein and lead to durable remissions.
How similar studies have performed: Early-phase clinical work with E7-directed TCR-T cells has shown safety and some clinical responses, but larger studies are needed to confirm lasting benefit.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Hinrichs, Christian — Rutgers Biomedical and Health Sciences
- Study coordinator: Hinrichs, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.